Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly Income from Continuing Operations came in at 50003000.0 in Q1 2026, down 144.3% year-on-year from 112879000.0 in Q1 2025, and up 19.91% quarter-over-quarter from 62436000.0 in Q4 2025.
Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 50003000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 144.3% year-over-year to 50003000.0 in Q1 2026; TTM through Mar 2026 was 174269000.0, a 478.76% decrease from a year earlier, with the FY2025 full-year figure at 204286000.0, down 67.55% from the prior year.
- Income from Continuing Operations rose to 50003000.0 in Q1 2026 per STOK's latest filing, from 62436000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 112879000.0 in Q1 2025 and bottomed at 162769000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 27174000.0 (2023), against an average of 36375588.24.
- Biggest YoY gain for Income from Continuing Operations was 527.99% in 2025; the steepest drop was 323.5% in 2025.
- Year by year, Income from Continuing Operations stood at 124548000.0 in 2022, then slumped by 30.69% to 162769000.0 in 2023, then surged by 90.94% to 14743000.0 in 2024, then tumbled by 323.5% to 62436000.0 in 2025, then rose by 19.91% to 50003000.0 in 2026.
- Per Business Quant, the three latest STOK Income from Continuing Operations figures stand at 50003000.0 (Q1 2026), 62436000.0 (Q4 2025), and 38347000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -50.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -62.44 Mn |
| Sep 30, 2025 | -38.35 Mn |
| Jun 30, 2025 | -23.48 Mn |
| Mar 31, 2025 | 112.88 Mn |
| Dec 31, 2024 | -14.74 Mn |
| Sep 30, 2024 | -26.43 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -26.37 Mn |
| Dec 31, 2023 | -162.77 Mn |
| Sep 30, 2023 | -27.17 Mn |
| Jun 30, 2023 | -37.09 Mn |
| Mar 31, 2023 | -24.71 Mn |
| Dec 31, 2022 | -124.55 Mn |
| Sep 30, 2022 | -29.28 Mn |
| Jun 30, 2022 | -32.19 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -89.65 Mn |
| Sep 30, 2021 | -25.27 Mn |
| Jun 30, 2021 | -22.58 Mn |